Lobeglitazone - Isotope Labelled Standards
References
FAQ's
References
- Hong, Chung-Il; Ahn, Soon-Kil; Kim, Bok-Young; Ahn, Joong-Bok; Lee, Do-Young; Lee, Hong-Woo; Shin, Jae-Soo, Thiazolidinedione derivatives and pharmaceutical composition comprising the same, WO03080605A1, Mar 28, 2002, Chong Kun Dang Pharmaceutical Corp. Republic of Korea. (https://patents.google.com/patent/WO2003080605A1/und)
- Kim, Bora; Shin, Hyun-Suk; Kim, Jung-Ryul; Lim, Kyung-Soo; Yoon, Seo Hyun; Yu, Kyung-Sang; Shin, Sang-Goo; Jang, In-Jin; Cho, Joo-Youn, Quantitative and Qualitative Analysis of CKD-501, Lobeglitazone, in Human Plasma and Urine Using LC-MS/MS and Its Application to a Pharmacokinetic Study, Chromatographia, Volume: 75, Issue: 11-12, Pages: 671-677, 2012 DOI: (10.1007/s10337-012-2238-0)
Frequently Asked Questions
Under what conditions does Lobeglitazone degrade?
Lobeglitazone degrades on exposure to light, moisture, and oxidation conditions.
Which analytical method can identify and separate the degradation products of Lobeglitazone present in the drug?
Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) can identify and separate the degradation products of Lobeglitazone.
Why is it essential to remove Lobeglitazone impurities from the drug?
Lobeglitazone impurities can affect the drug's quality, safety, and efficacy. Hence, it is essential to remove them from the drug.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.